Earnings Alert: Cidara Therapeutics Inc. (NASDAQ: CDTX)

Dorothy Owen

I am Dorothy Owen and I give “Seeking Review” an insight into the most recent news hitting the “Healthcare” sector in Wall Street.

I have been an independent financial adviser for over 11 years in the city and in recent years turned my experience in finance and passion for journalism into a full time role. I perform analysis of Companies and publicize valuable information for shareholder community.

Address: 454 Cottrill Lane, Saint Louis, MO 63108, USA
Phone: (+1) 314-388-9712
Email: dorothy.owen@seekingreview.com
Dorothy Owen

SAN DIEGO, August 12, 2019 – Shares of Cidara Therapeutics Inc. (NASDAQ: CDTX) showed no change to $1.30. The stock grabbed the investor’s attention and traded 104.571K shares as compared to its average daily volume of 161.04K shares. The stock’s institutional ownership stands at 69.20%.

Cidara Therapeutics, Inc. (CDTX) reported net loss of $16.60M for the three months ended March 31, 2019, contrast to a net loss of $16.70M for the first quarter of 2018.

First Quarter 2019 Financial Results:

  • Cash, cash equivalents and short-term investments totaled $57.40M as of March 31, 2019, contrast with $74.60M as of December 31, 2018.
  • As of April 30, 2019, Cidara had 26.641M shares of common stock outstanding and 565.231K shares of Series X convertible preferred stock outstanding, which are convertible into 5.652M shares of common stock.
  • Research and development expenses were $12.70M for the three months ended March 31, 2019, contrast to $13.20M for the same period in 2018. The decrease was mainly attributable to clinical development activities for rezafungin.
  • General and administrative expenses were $3.70M for the three months ended March 31, 2019, contrast to $3.60M for the same period in 2018.

CDTX has a market value of $35.19M while its EPS was booked as $-2.66 in the last 12 months. The stock has 27.07M shares outstanding. Beta value of the company was 2.17; beta is used to measure riskiness of the security. Analyst recommendation for this stock stands at 1.80.

Dorothy Owen

Dorothy Owen

I am Dorothy Owen and I give “Seeking Review” an insight into the most recent news hitting the “Healthcare” sector in Wall Street. I have been an independent financial adviser for over 11 years in the city and in recent years turned my experience in finance and passion for journalism into a full time role. I perform analysis of Companies and publicize valuable information for shareholder community. Address: 454 Cottrill Lane, Saint Louis, MO 63108, USA Phone: (+1) 314-388-9712 Email: dorothy.owen@seekingreview.com